These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36865172)

  • 41. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
    Day CL; Tameris M; Mansoor N; van Rooyen M; de Kock M; Geldenhuys H; Erasmus M; Makhethe L; Hughes EJ; Gelderbloem S; Bollaerts A; Bourguignon P; Cohen J; Demoitié MA; Mettens P; Moris P; Sadoff JC; Hawkridge A; Hussey GD; Mahomed H; Ofori-Anyinam O; Hanekom WA
    Am J Respir Crit Care Med; 2013 Aug; 188(4):492-502. PubMed ID: 23306546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.
    Rodrigues LC; Pereira SM; Cunha SS; Genser B; Ichihara MY; de Brito SC; Hijjar MA; Dourado I; Cruz AA; Sant'Anna C; Bierrenbach AL; Barreto ML
    Lancet; 2005 Oct; 366(9493):1290-5. PubMed ID: 16214599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review.
    Machlaurin A; Pol SV; Setiawan D; van der Werf TS; Postma MJ
    Expert Rev Vaccines; 2019 Sep; 18(9):897-911. PubMed ID: 31369299
    [No Abstract]   [Full Text] [Related]  

  • 44. [BCG vaccines for the prevention of tuberculosis in the world].
    Hashimoto T
    Kekkaku; 1997 Nov; 72(11):629-37. PubMed ID: 9423301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
    Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
    EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis.
    Jayawardana S; Weerasuriya CK; Pelzer PT; Seeley J; Harris RC; Tameris M; Tait D; White RG; Asaria M
    NPJ Vaccines; 2022 Nov; 7(1):138. PubMed ID: 36344523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.
    Darrah PA; DiFazio RM; Maiello P; Gideon HP; Myers AJ; Rodgers MA; Hackney JA; Lindenstrom T; Evans T; Scanga CA; Prikhodko V; Andersen P; Lin PL; Laddy D; Roederer M; Seder RA; Flynn JL
    NPJ Vaccines; 2019; 4():21. PubMed ID: 31149352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial.
    Barreto ML; Pereira SM; Pilger D; Cruz AA; Cunha SS; Sant'Anna C; Ichihara MY; Genser B; Rodrigues LC
    Vaccine; 2011 Jul; 29(31):4875-7. PubMed ID: 21616115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BCG vaccination strategies against tuberculosis: updates and perspectives.
    Qu M; Zhou X; Li H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5284-5295. PubMed ID: 34856853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
    Clark S; Lanni F; Marinova D; Rayner E; Martin C; Williams A
    J Infect Dis; 2017 Sep; 216(5):525-533. PubMed ID: 28329234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study.
    Roy P; Vekemans J; Clark A; Sanderson C; Harris RC; White RG
    Lancet Glob Health; 2019 Dec; 7(12):e1655-e1663. PubMed ID: 31708146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
    Constenla D; Liu T
    Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is neglect of self-clearance biasing TB vaccine impact estimates?
    Scarponi D; Clark RA; Weerasuriya CK; Emery J; Houben RMGJ; White R; McCreesh N
    BMJ Glob Health; 2023 Aug; 8(8):. PubMed ID: 37558271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0-4 years.
    Thysen SM; Fisker AB; Byberg S; Aaby P; Roy P; White R; Griffiths U; Harris RC
    BMJ Glob Health; 2021 Aug; 6(8):. PubMed ID: 34344667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Causes of variation in BCG vaccine efficacy: examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses.
    Barreto ML; Pilger D; Pereira SM; Genser B; Cruz AA; Cunha SS; Sant'Anna C; Hijjar MA; Ichihara MY; Rodrigues LC
    Vaccine; 2014 Jun; 32(30):3759-64. PubMed ID: 24852722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The quest for vaccine-induced immune correlates of protection against tuberculosis.
    Nemes E; Fiore-Gartland A; Boggiano C; Coccia M; D'Souza P; Gilbert P; Ginsberg A; Hyrien O; Laddy D; Makar K; McElrath MJ; Ramachandra L; Schmidt AC; Shororbani S; Sunshine J; Tomaras G; Yu WH; Scriba TJ; Frahm N;
    Vaccine Insights; 2022 Jul; 1(3):165-181. PubMed ID: 37091190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.
    Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Deol A; Scarponi D; Iskauskas A; Bakker R; Quaife M; Malhotra S; Gebreselassie N; Zignol M; Hutubessy RCW; Giersing B; Jit M; Harris RC; Menzies NA; White RG
    Lancet Glob Health; 2023 Apr; 11(4):e546-e555. PubMed ID: 36925175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease.
    Velayutham B; Thiruvengadam K; Kumaran PP; Watson B; Rajendran K; Padmapriyadarsini C
    Indian J Med Res; 2023; 157(2&3):152-159. PubMed ID: 36124494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The status of tuberculosis vaccine development.
    Schrager LK; Vekemens J; Drager N; Lewinsohn DM; Olesen OF
    Lancet Infect Dis; 2020 Mar; 20(3):e28-e37. PubMed ID: 32014117
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.